To systematically quantify the prevalence of CPK elevation in patients with Atopic Dermatitis (AD) who are receiving JAK inhibitors or Dupilumab, and whether there are clinically significant outcomes
To systematically quantify the prevalence of CPK elevation in patients with Atopic Dermatitis (AD) who are receiving JAK inhibitors or Dupilumab, and whether there are clinically significant outcomes
To systematically quantify the prevalence of CPK elevation in patients with Atopic Dermatitis (AD) who are receiving JAK inhibitors or Dupilumab, and whether there are clinically significant outcomes